LGALS9
| Official symbol: | LGALS9 |
| Full name: | galectin 9 |
| Location: | 17q11.2 |
| Also known as: | LGALS9A |
| Entrez ID: | 3965 |
| Ensembl ID: | ENSG00000168961 |
| Summary: | |
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
| Gscore (Amp): | 0.00 | | Gscore (Del): | 0.00 |
|
|
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
|
| |
|
|
|
| |
Overall
|
|
Tissue specific
|
| |
| Total fusion occurrence: | NA |
|
|
|
| |
|
|
|
| Functional class: | Not specified |
| JensenLab PubMed score: | 196.69 (Percentile rank: 81.50%) |
| PubTator score: | 166.98 (Percentile rank: 83.96%) |
| Target development/druggability level: | TchemThese targets have activities in ChEMBL or DrugCentral that satisfy the activity thresholds detailed below. |
| Tractability (small molecule): | Discovery PrecedenceTargets with ligands; Targets with crystal structures with ligands |
| Tractability (antibody): | Predicted Tractable - High confidenceTargets located in the plasma membrane; Targets with GO cell component terms plasma membrane or secreted |
